Adult Growth Hormone Deficiency and Cardiovascular Risk
| Status: | Terminated |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 19 - 65 |
| Updated: | 10/14/2017 |
| Start Date: | February 2007 |
| End Date: | May 2011 |
Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas
This protocol will assess the cardiovascular risk associated with growth hormone deficiency
in adults. We will use multiple modalities to assess risk for heart attacks or strokes
including blood work, ultrasound, MRI and endothelial cell biopsies in both patients who are
growth hormone deficient and in patients with normal growth hormone secretion. We hypothesize
that adults with growth hormone deficiency will have results suggestive of an increased risk
for cardiovascular disease.
in adults. We will use multiple modalities to assess risk for heart attacks or strokes
including blood work, ultrasound, MRI and endothelial cell biopsies in both patients who are
growth hormone deficient and in patients with normal growth hormone secretion. We hypothesize
that adults with growth hormone deficiency will have results suggestive of an increased risk
for cardiovascular disease.
Subjects will first be tested for possible growth hormone deficiency. This will be done by
administering two intravenous medications that should stimulate growth hormone secretion and
we will measure growth hormone in the blood every 30 minutes following the administration.
Once we have the results on enough subjects we will split the cohort into those subjects who
are growth hormone deficient and those who have normal growth hormone. The two groups will
each undergo various tests all designed to assess some component of cardiovascular risk.
Ultimately we will compare the results of each test to see if those who are growth hormone
deficient have an increased risk for cardiovascular disease.
administering two intravenous medications that should stimulate growth hormone secretion and
we will measure growth hormone in the blood every 30 minutes following the administration.
Once we have the results on enough subjects we will split the cohort into those subjects who
are growth hormone deficient and those who have normal growth hormone. The two groups will
each undergo various tests all designed to assess some component of cardiovascular risk.
Ultimately we will compare the results of each test to see if those who are growth hormone
deficient have an increased risk for cardiovascular disease.
Inclusion Criteria:
- Adults 19 years or older who have undergone transsphenoidal surgery for a clinically
non-secreting pituitary adenoma
Exclusion Criteria:
- Currently taking growth hormone, radiation therapy in the past 5 years, changes in
dose of other pituitary hormone replacement therapy in past 3 months, taking
hydrocortisone (or its equivalent) at a dose of > 30 mg/day, pregnant or nursing women
We found this trial at
1
site
Click here to add this to my saved trials
